Navigation Links
Cord Blood America Says Balance Sheet Significantly Strengthened in 2009
Date:8/17/2009

SANTA MONICA, Calif., Aug. 17 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that its 10Q filing with the U.S. Securities & Exchange Commission for the second quarter of 2009 shows a significantly improved balance sheet.

At June 30, 2009, Cord Blood America's working capital had increased by almost $4 million compared to year-end 2008. This is a 90 percent improvement in only six months.

The Company also had a balance of $324,549 in cash, an important increase as Cord Blood America moves forward with organic growth and possible acquisitions.

Further the 10Q has a schedule detailing the repayment of $5 million in debt in the first half of the year, one of the pillars needed for the Company to succeed.

"While revenues were down, due to very difficult economic conditions, and a significant de-emphasis on our advertising business, we are confident we have built the strong foundation necessary for the growth our shareholders want," said Matthew Schissler, founder and CEO.

"In addition, we anticipated being cash flow positive this year. However one time charges in Q2 including the cost of capital for the $7.5M raised, and significant testing and auditing of our SOP's, coupled with the excellent opportunity to build one of the largest stem cell storage facilities in the country, delayed this in the short term. There were significant sunk costs in Q2 that couldn't be avoided. All measures were taken to strengthen CBAI for the long term."

Mr. Schissler concluded: "Once the stem cell storage and research and development lab in Las Vegas is completed, CBAI will immediately increase our gross margins, bringing us closer to cash flow positive."

The 10Q can be found in its entirety at www.sec.gov.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate,'' "believe,'' "expect,'' "future,'' "intend,'' "plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

    CONTACT:
    Paul Knopick
    E & E Communications
    949/707-5365
    pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Heroes of Chemistry for saving teeth, clean water, new high blood pressure drug
2. Bayer Statement on U.S. Food and Drug Administration Advice for Patients: Serious Errors with Certain Blood Glucose Monitoring Test Strips
3. BD and PEPFAR Collaboration Will Improve Blood-Drawing Practices in Hospitals and Clinics in Sub-Saharan Africa
4. MRI Simulation of Blood Flow Helps Plan Childs Heart Surgery
5. Cold, Flu or Pneumonia? Answer May Lie in Blood Test
6. U.S. Navy Awards Entegrion Contracts for $4 Million for the Development of Critical Blood Products
7. Memorial Blood Centers Joins Extreme Makeover: Home Edition As Designated Charity
8. Blood transfusion study: Less is more
9. Gut Hormone Could be Key to Blood Sugar
10. GenVaults GenSolve(TM) Reagents Enable State-of-the-Art Genomic Analysis of Dried Blood Spots
11. Silenced genes as a warning sign of blood cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans ... important that we all are aware of our options and are empowered with ... announce the launch of its newest edition of "Vision and Hearing" in USA ...
(Date:2/24/2017)... Viejo, CA (PRWEB) , ... February 24, 2017 , ... ... Final Cut Pro X . Users have total control over position, rotation, distortion, ... and more all within Final Cut Pro X. , With ProGlass Prism users are ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) ... You See” body image mannequin art competition. Selected from 15 submissions from around the ... revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
Breaking Medicine Technology: